The makers of Kaopectate agreed Thursday to reformulate all of its popular antidiarrhea products so they no longer contain potentially harmful levels of lead. A Superior Court judge in San Francisco ...
The maker of the popular anti-diarrhea medicine Kaopectate has agreed to reduce levels of toxic lead in its product as part of a settlement with state Attorney General Bill Lockyer. The state sued ...
Except for Lil' Drug Store, the other defendants in the case, including RiteAid, Walgreens, Hi-Tech Pharmacal and Columbia Laboratories, have not settled (Say, San Francisco Chronicle, 6/27). Lil' ...
SAN FRANCISCO (AP) -- Addressing a potential health threat in a product millions of parents have given their children, the maker of the anti-diarrhea medicine Kaopectate agreed to slash its lead ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
The maker of Kaopectate, the top anti-diarrhea remedy in the U.S., has agreed to cut lead levels in its caplets. The move comes as part of a settlement with California. The caplets contain 25 ...
Arcadia Consumer Healthcare Inc, which is backed by Avista Capital Partners, has acquired anti-diarrheal medicine Kaopectate from Sanofi. No financial terms were disclosed. NEW YORK, March 20, 2020 ...
Addressing a potential health threat in a product millions of parents have given their children, the maker of the anti-diarrhea medicine Kaopectate agreed to slash its lead levels in a settlement with ...
Addressing a potential health threat in a product millions of parents have given their children, the maker of the anti-diarrhea medicine Kaopectate agreed to slash its lead levels in a settlement with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback